V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Silk Road Medical Executive Compensation (FY23)

SILK · Executive and director compensation, fiscal 2022 to 2023

The paid brief on Silk Road Medical

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 12, 2026Latest filing (8-K): June 20, 2024
5 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Silk Road Medical brief$1,500Get the executive brief
245 figures on this page: 241 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
Chief executive, fiscal 2023
◇
Chas McKhann
Median of the other named officers
$4,866,640
5 officers, excluding the chief executive
Latest say-on-pay support
=
June 18, 2024

More on Silk Road Medical

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2022 to fiscal 2023
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Erica Rogers → Chas McKhann

Frequently asked questions

Answers drawn from the data on this page.
Who is Silk Road Medical's chief executive and what were they paid?
Chas McKhann was paid $13,423,834 in total compensation as Chief Executive Officer for fiscal 2023.
What was Silk Road Medical's say-on-pay result?
For fiscal 2023, shareholders backed the say-on-pay proposal with 82.4% of votes cast for or against in favor at the meeting held June 18, 2024.
Which companies are in Silk Road Medical's peer group?
The disclosed peer group includes Alphatec Holdings, Inc., AtriCure, Inc., Glaukos Corporation, Inari Medical, Inc. and Outset Medical, Inc.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Erica Rogers
Former President and Chief Executive Officer
◇—◇◇◇—◇◇
Lucas Buchanan
Chief Operating Officer and Chief Financial Officer
◇—◇◇◇—◇◇
Andrew Davis
Chief Commercial Officer
◇—◇◇◇—◇◇
Kevin Klemz
Executive Vice President, Chief Legal Officer and Secretary
◇◇◇◇◇—◇◇
Richard Ruedy
Executive Vice President of Regulatory and Clinical Affairs and Quality Assurance
◇◇◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Chas McKhann
Chief Executive Officer
◇◇◇—◇—◇◇
Erica Rogers
Former President and Chief Executive Officer
Departed during or after this year
◇—◇◇◇—◇◇
Lucas Buchanan
Chief Operating Officer and Chief Financial Officer
◇—◇—◇—◇◇
Andrew Davis
Chief Commercial Officer
◇◇◇—◇—◇◇
Kevin Klemz
Executive Vice President, Chief Legal Officer and Secretary
◇—◇—◇—◇◇
Richard Ruedy
Executive Vice President of Regulatory and Clinical Affairs and Quality Assurance
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2023
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Andrew S. DavisPSU◇◇◇◇◇—◇
Andrew S. DavisRSU◇——◇——◇
Chas S. McKhannPSU◇◇◇◇◇—◇
Erica J. RogersPSU◇◇◇◇◇—◇
Lucas W. BuchananPSU◇◇◇◇◇—◇
Lucas W. BuchananRSU◇——◇——◇
Lucas W. BuchananRSU◇——◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2023 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Richard RuedyOption◇—◇03/01/2031
Option◇—◇03/02/2032
RSU◇◇——
Option◇—◇03/27/2030
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Andrew DavisOption◇—◇03/01/2031
Option◇—◇08/13/2030
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇03/27/2030
PSU◇◇——
RSU◇◇——
Option◇—◇03/02/2032
RSU◇◇——
RSU◇◇——
Lucas BuchananOption◇—◇03/02/2032
Option◇—◇03/02/2032
Option◇—◇03/27/2030
RSU◇◇——
Option◇—◇11/06/2030
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇03/01/2031
RSU◇◇——
RSU◇◇——
RSU◇◇——
Erica RogersOption◇—◇11/02/2026
Option◇—◇11/02/2026
Option◇—◇11/02/2026
Option◇—◇11/02/2026
Kevin KlemzOption◇—◇08/15/2032
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Chas McKhannPSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2023
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jack W. Lasersohn
Board chair
◇◇◇———◇
Donald J. Zurbay
◇◇————◇
Rick D. Anderson
◇◇◇———◇
Kevin J. Ballinger
◇◇◇———◇
Elizabeth H. Weatherman
◇◇◇———◇
Tanisha V. Carino, Ph.D
◇◇◇———◇
Tony M. Chou, M.D
◇◇◇———◇
Chas S. McKhann served on the board in fiscal 2023 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2023
  • Alphatec Holdings, Inc. ATEC
  • AtriCure, Inc. ATRC
  • Glaukos Corporation GKOS
  • Inari Medical, Inc. NARI
  • Outset Medical, Inc. OM

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2023June 18, 2024=◇◇◇
2022June 21, 2023=◇◇◇
2021June 9, 2022=◇◇◇
2020June 17, 2021=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Silk Road Medical files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Silk Road Medical disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Silk Road Medical sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Silk Road Medical's disclosed peer group is defensible, who names Silk Road Medical back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
245 figures on this page: 241 cited to the filing that reported them, 4 calculated from figures it prints.
241 cited to the filing
4 calculated from the filing

Documents cited

  1. 0001397702-24-000040
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  2. 0001397702-24-000024
    DIRECTOR COMPENSATION · GRANTS OF PLAN-BASED AWARDS DURING 2023 · Grants of Plan-Based Awards
  3. 0001397702-23-000046
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  4. 0001397702-22-000037
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  5. 0001397702-21-000044
    I tem 5.07. Submission of Matters to a Vote of Security Holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Silk Road Medical executive compensation, FY2022–FY2023.” https://intel.velarion.ai/comp/SILK (accessed 2026).
Short form: data: Velarion

The paid brief for Silk Road Medical

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Silk Road Medical and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Silk Road Medical discloses

The companies named in SILK's own disclosed peer group.

Alphatec Holdings, Inc.AtriCure, Inc.Glaukos CorporationInari Medical, Inc.Outset Medical, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy